Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02925104 · ClinicalTrials.gov registry record · Phase 1
A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.
A Phase 1 study of cMET Dysegulation Advanced Solid Tumors, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 17
- Study locations
NCT02925104 is a Phase 1 study of cMET Dysegulation Advanced Solid Tumors that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 36 participants. The trial reports 17 study locations across 4 states.
The verdict
NCT02925104, a Phase 1 study of cMET Dysegulation Advanced Solid Tumors, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 17
- Study locations
Study Summary
Dose escalation study to assess PK, safety and tolerability of INC280 when taken with food in patients with cMET dysregulated advanced solid tumors.
Conditions Studied
Interventions
- DRUG INC280
Study Locations (17)
Other
- Novartis Investigative Site - Salzburg
- Novartis Investigative Site - Herlev
- Novartis Investigative Site - Dresden
- Novartis Investigative Site - Mainz
- Novartis Investigative Site - Nijmegen
- Novartis Investigative Site - Barcelona
- Novartis Investigative Site - Madrid
- Novartis Investigative Site - Zaragoza
- Novartis Investigative Site - Gothenburg
- Novartis Investigative Site - Lund
- Novartis Investigative Site - Stockholm
- Novartis Investigative Site - Uppsala
- Novartis Investigative Site - London
- Novartis Investigative Site - Manchester
Indiana
- Indiana University Simon Cancer Center SC - Indianapolis
Andalusia
- Novartis Investigative Site - Málaga
Galicia
- Novartis Investigative Site - Santiago de Compostela
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2016-12-14 |
| Est. Completion | 2018-05-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02925104
The ClinicalTrials.gov registry entry for NCT02925104 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with cMET Dysegulation Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which INC280 is the first listed.
NCT02925104 reports 17 study locations spanning 4 distinct geographic areas - top geographies include Other, Indiana, Andalusia.
Frequently Asked Questions
What is clinical trial NCT02925104 about?
NCT02925104 is a clinical study titled "A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.". Dose escalation study to assess PK, safety and tolerability of INC280 when taken with food in patients with cMET dysregulated advanced solid tumors.
What is the current status of trial NCT02925104?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2016-12-14. Estimated completion is 2018-05-16.
What conditions does trial NCT02925104 study?
This clinical trial studies the following conditions: cMET Dysegulation Advanced Solid Tumors.
What interventions are being tested in trial NCT02925104?
The interventions under investigation include: INC280 (DRUG).
Who is sponsoring clinical trial NCT02925104?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02925104 being conducted?
This trial has 17 study locations across Indiana, Andalusia, Galicia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.